ChemicalBook
Chinese english Germany Japanese Korea

Buprenorphin Produkt Beschreibung

BUPRENORPHINE Struktur
52485-79-7
CAS-Nr.
52485-79-7
Bezeichnung:
Buprenorphin
Englisch Name:
BUPRENORPHINE
Synonyma:
UM-952;rx6029m;Lepetan;Subutex;Temgesi;NIH-8805;Buprenex;Temgesic;CL-112302;Buprenorfin
CBNumber:
CB0279103
Summenformel:
C29H41NO4
Molgewicht:
467.65
MOL-Datei:
52485-79-7.mol

Buprenorphin Eigenschaften

Schmelzpunkt:
260-262°C
Siedepunkt:
570.1°C (rough estimate)
Dichte
1.0953 (rough estimate)
Brechungsindex
1.6290 (estimate)
Flammpunkt:
9℃
storage temp. 
-20°C
Löslichkeit
Very slightly soluble in water, freely soluble in acetone, soluble in methanol, slightly soluble in cyclohexane. It dissolves in dilute solutions of acids.
pka
pKa 8.24(H2O t=23.0±0.3) (Uncertain)
CAS Datenbank
52485-79-7
EPA chemische Informationen
6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-.alpha.-methyl-, (.alpha.S,5.alpha.,7.alpha.)- (52485-79-7)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher F,T
R-Sätze: 11-23/24/25-39/23/24/25
S-Sätze: 16-36/37-45-7
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  1
Toxizität LD50 oral in mouse: 260mg/kg
Bildanzeige (GHS)
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H225 Flüssigkeit und Dampf leicht entzündbar. Entzündbare Flüssigkeiten Kategorie 2 Achtung P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 Schädigt die Organe. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 1 Achtung P260, P264, P270, P307+P311, P321,P405, P501
Sicherheit
P210 Von Hitze, heißen Oberflächen, Funken, offenen Flammen und anderen Zündquellenarten fernhalten. Nicht rauchen.
P260 Dampf/Aerosol/Nebel nicht einatmen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P311 GIFTINFORMATIONSZENTRUM/Arzt anrufen.
P301+P310 BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

Buprenorphin Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften

White Solid

Verwenden

Controllled substance (narcotic). Analgesic that demonstrates narcotic agonist-antagonist properties.

Definition

ChEBI: A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is su stituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group.

Trademarks

Buprenex (Reckitt Benckiser); Subutex (Reckitt Benckiser);Buprex;Buprx;Finibron;Prefin;Temagesic.

Weltgesundheitsorganisation (WHO)

Buprenorphine, an opioid analgesic with both morphine agonist and antagonist activity, was introduced in 1978. It was originally considered to possess low dependence potential. However, it has latterly been identified as causing a socially significant abuse problem in several countries which have consequently subjected it to control in 1989 under Schedule III of the 1971 Convention of Psychotropic Substances. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)

Biologische Funktion

Buprenorphine (Temgesic) is a mixed agonist–antagonist and a derivative of the naturally occurring opioid thebaine. Buprenorphine is highly lipophilic and is 25 to 50 times more potent than morphine as an analgesic. The sedation and respiratory depression it causes are more intense and longer lasting than those produced by morphine. Its respiratory depressant effects are not readily reversed by naloxone. It binds to the -receptor with high affinity and only slowly dissociates from the receptor, which may explain the lack of naloxone reversal of respiratory depression.
Buprenorphine has more agonist than antagonist effects and is often considered a partial agonist rather than a mixed agonist–antagonist, although it precipitates withdrawal in opioid-dependent patients. Its pharmacological effects are similar to those produced by both morphine and pentazocine. Indications for its use are similar to those of pentazocine, that is, for moderate to severe pain. Sublingual preparations are available, but have a slow onset and erratic absorption. The abuse potential of buprenorphine is low.While high doses of the drug are perceived by addicts as being morphinelike, it does reduce the craving for morphine and for the stimulant cocaine. Thus, buprenorphine is a potential new therapy for the treatment of addiction to both classes of drugs.
Drug interactions and contraindications are similar to those described for pentazocine and morphine.

Allgemeine Beschreibung

Buprenorphine is a semisynthetic, highly lipophilic opiate derivedfrom thebaine. Pharmacologically, it is classified as amixed μ-agonist/antagonist (a partial agonist) and a weak κ-antagonist. It has a high affinity for the μ-receptors(1,000 times greater than morphine) and a slow dissociationrate leading to its long duration of action (6–8 hours). Atrecommended doses, it acts as an agonist at the μ-receptorwith approximately 0.3 mg IV equianalgesic to 10 mg of IVmorphine. One study in humans found that buprenorphine displaysa ceiling effect to the respiratory depression, but not theanalgesic effect over a dose range of 0.05 to 0.6 mg.In practice,this makes buprenorphine a safer opiate (when usedalone) than pure μ-agonists. Relatively few deaths frombuprenorphine overdose (when used alone) have been reported.113 The tight binding of the drug to the receptor also hasled to mixed reports on the effectiveness of using naloxone toreverse the respiratory depression. In animal studies, normaldoses of the pure antagonist naloxone were unable to removebuprenorphine from the receptor site and precipitate withdrawal.In a human study designed to precipitate withdrawalfrom buprenorphine, a naloxone dose (mean=35 mg) 100times the dose usually needed to precipitate withdrawal inmethadone-dependent subjects was used. For comparison, approximately0.3 mg, 4 mg, 4 mg, and 10 mg of naloxonewould be required to precipitate withdrawal from heroin, butorphanol,nalbuphine, or pentazocine respectively.

Kontakt-Allergie

This semisynthetic opioid analgesic drug is derived fromwith transdermal systems (TDS). In case of localized or generalized allergic contact dermatitis due to buprenorphine in TDS, TDS containing fentanyl can be safely used thebaine. It can be used parenterally, orally, and topically

Buprenorphin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Buprenorphin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 0)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate

52485-79-7(Buprenorphin)Verwandte Suche:


  • 6,14-ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-alpha-(1,1-dimethylethy
  • l)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,(5-alpha,7-alpha
  • rx6029m
  • BUPRENORPHINE
  • BUPRENORPHINE BASE
  • [5a,7a(S)]-17-(Cyclopropylmethyl)-a-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-a-methyl-6,14-ethenomorphinan-7-methanol Hydrochloride
  • Buprenex
  • CL-112302
  • Lepetan
  • NIH-8805
  • Subutex
  • Temgesi
  • UM-952
  • 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-.alpha.-methyl-, (.alpha.S,5.alpha.,7.alpha.)-
  • BUPRENOPHINE
  • 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, (αS,5α,7α)-
  • 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, [5α,7α(S)]-
  • Temgesic
  • Buprenorphine (base and/or unspecified salts)
  • [5a,7a(S)]-17-(Cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol Hydrochloride
  • BuprenorphineBase(Narcotic)C29H41No4,Edmf
  • Buprenorphine Base (Narcotic)
  • Buprenorphine solution
  • (αS)-17-(Cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5α-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7α-methanol
  • Buprenorfin
  • Methanol (test Buprenorphine,100ug/mL)
  • (4R,4aS,6R,7R,7aR,12bS)-3-(cyclopropylmethyl)-6-((S)-2-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
  • Buprenorphine (1.0mg/ml in Acetonitrile)
  • Buprenorphine EP Impurity A
  • Buprenorphine EP Impurity B
  • Buprenorphine EP Impurity C
  • Buprenorphine EP Impurity D
  • Buprenorphine EP Impurity E
  • Buprenorphine EP Impurity F
  • Buprenorphine EP Impurity G
  • Buprenorphine EP Impurity H
  • Buprenorphine EP Impurity I
  • Buprenorphine EP Impurity J
  • 52485-79-7
  • 652485-79-7
  • C29H41NO4
  • C29H42ClNO4
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • PHARMACEUTICAL INTERMEDIATE
Copyright 2019 © ChemicalBook. All rights reserved